Prostate Cancer, Farming and Other Risk Factors: A Mini Review

Prostate cancer is the fourth most common cancer and is the second most frequently diagnosed cancer among men.

Studies have suggested that an increased risk of prostate cancer among men may be associated with age, race/ ethnicity and family history of cancer.

The etiology of prostate cancer is not precisely known with respect to other putative risk factors such as farming, exposure to pesticides and lifestyle factors. Therefore, the purpose of this paper was to review the published literature to identify some of the potential risk factors of prostate cancer.

PDF LINK

Stereotactic Radiotherapy for Localized Prostate Cancer, which is Better CyberKnife or RapidArc?

We aim to compare two different stereotactic body radiation therapy (SBRT) techniques, non-isocentric CyberKnife (CK) with isocentric RapidArc (RA), more widely available treatment technique for the treatment of localized prostate cancer.

The study included six patients treated with CK then re-planned with the new version of flattening filter free (FFF) RA and CK. The prescription dose was 36.25 Gy in five fractions. The two SBRT techniques were compared by target coverage, normal tissue sparing, dose distribution parameters and delivery time.

The RA technique exhibited comparable PTV coverage and better bladder and rectum sparing at high doses. The conformity and homogeneity indices of the RA were better and statistically significant than the CK plans.

PDF LINK

Exceptional Therapeutic Outcome of Metastatic Neuroendocrine Tumor with Peptide Receptor Radionuclide Therapy with Brief Review of Literature

NETs are rare, heterogeneous group of neoplasm presented as chronic oncologic disease. Somatostatin analogue is the standard first line systemic therapy for mainly hormone control.

No standard second line systemic treatment is available except everolimus which has no reported complete response. PRRT is an innovative molecular targeted treatment based on theragnostic concept for well differentiated NETs.

We presented here a 63-year-old lady with grade 1 NET of rectum with lymphnodal and liver metastasis. She underwent sigmoid colostomy for bowel symptoms and started on sandostatin LAR.

PDF LINK

Clinical Outcomes of Grade 3 Giant Cell Tumor of Bone After Extended Intralesional Curettage

The recommended treatment of grade 3 giant cell tumor of bone (grade 3 GCTB) aims to eliminate tumor and conserve limb with extended intralesional curettage.

This treatment makes patients better function of bone and joint as usual. Even it can reduce postoperative complications and replace endoprosthesis. Still, there is limited information about the outcomes of surgical treatment and recurrence of the disease.

This study aimed to evaluate the clinical outcomes and recurrence of grade 3 GCTB with extended intralesional curettage.

PDF LINK

Measuring Intratumoral Metabolic Heterogeneity by Positron Emission Tomography in Cervical Cancer

Measurement of intratumoral heterogeneity by 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET) is a valuable modality, which showed correlation to response of treatment and prognosis in various malignancies.

PET-based texture analysis for tumor heterogeneity is a potential predictive factor for cervical cancer and related to lymph node metastasis, tumor volume, response of treatment, and pelvic recurrence.

Although seemed promising in utility in oncology, a plenty of methods have been used for analysis of heterogeneity which led to confusion of definitions and comparing results challenging. Further larger sized prospective studies are needed for standardized heterogeneity descriptors and clinical applications.

PDF LINK

Breast Cancer and Pregnancy: Experience of Maternity and Neonatology Center of Tunis-Tunisia

This document aims to identify the clinical, therapeutic, and prognostic features of this association and to provide the up-to-date management.

Our study design is retrospective based on 25 cases of pregnancy-associated breast cancer, carried out at the Maternity and Neonatology Center of Tunis over a period of 10 years, between January 2001 and December 2013.

The mean age of the patients was 35.84 years. Breast cancer was diagnosed during pregnancy in fourteen patients and after delivery in eleven patients. Pathohistological diagnosis was established by ultrasoundguided biopsy and surgical biopsy in fourteen and seven patients, respectively.

PDF LINK

The Hematologic Toxicity of Methotrexate in Patients with Autoimmune Disorders

The incidence of auto-immune diseases is increasing nowa- days. Despite of the development of diagnosis and management of diseases, they remained chronic diseases.

The patient’s lifespan expansion requires long-term treatment with harmful agents, such as Methotrexate or other immuno-suppressive drugs. The Methotrexate toxicities are based on the duration and cumulative dosing of drug, and the combination with other drugs.

Myelosuppression and consequent pancytopenia is the most frequent hematologic toxicity, which occur mostly later during low dose methotrexate administration. We demonstrate three cases of low dose Methotrexate toxicity in older patients with rheumatoid arthritis and psoriasis.

PDF LINK